Global Dermal Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Product, By End-use (MedSpa, Cosmetic Surgery Clinics and Hospitals), By Application, By Regional Outlook and Forecast, 2023 - 2029

Global Dermal Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Product, By End-use (MedSpa, Cosmetic Surgery Clinics and Hospitals), By Application, By Regional Outlook and Forecast, 2023 - 2029

The Global Dermal Fillers Market size is expected to reach $10.3 billion by 2029, rising at a market growth of 8.1% CAGR during the forecast period.

The purpose of dermal fillers is to impart volume and fullness to the skin through injection. A mineral-like substance found in bones called calcium hydroxylapatite, polyalkylimide, hyaluronic acid, polylactic acid, and polymethyl-methacrylate microspheres is among the ingredients utilized in dermal fillers (PMMA).

In addition, the deep dermis, depth of implantation (superficial midterms and upper and subcutaneous levels), the longevity of correction (temporary and permanent), allergenicity, the agent's composition (allografts, semi/fully synthetic, xenografts, or autologous), and stimulatory behavior (physiologic processes of endogenous tissue proliferation) versus replacement fillers are some of the criteria that can be used to classify dermal fillers (space-replacing effect).

HA and collagen are two examples of temporary dermal fillers that are biodegradable and have a lifespan of between four and nine months. Both dissatisfaction and the possibility of detrimental effects are temporary occurrences.

Therefore, in order to save long-lasting fillers for subsequent patient visits, temporary fillers are always employed as the initial line of treatment. Permanent fillers are mostly utilized to treat deep skin wrinkles and furrows that go beyond the scope of typical face creases. They are considered a top choice for face rejuvenation, particularly in HIV lipodystrophy. PMMA is generally employed for effects that are effective, long-lasting, and safe.

COVID-19 Impact Analysis

The medical cosmetics industry experienced supply chain delays due to the COVID-19-imposed lockdowns, which included restrictions on import and export, flight cancellations, decreased production, and disrupted supply lines. Moreover, nonsurgical procedures involving hyaluronic acid and botulinum toxin saw a decline in total usage. Thus, the drop in product demand during the pandemic further impacted the market expansion. The market for dermal fillers has been affected by the COVID-19 pandemic. However, the market for dermal fillers will be driven by the relaxation of regulatory regulations after the decreasing cases of COVID-19, thereby aiding the market to recover after the losses during the pandemic.

Market Growth Factors

The rising popularity of injectable fillers among men

One of the most pervasive trends in the market is that practically all demographic groups have demonstrated a desire or predisposition for these minimally invasive or non-invasive procedures. For the male demographic, who are increasingly using these operations to improve their appearance, this is especially important. For instance, a growing number of men are discovering that gravity and aging can have a detrimental effect on the way their facial features look. As a result, males choose facial filler procedures due to their success in reversing the early gravitational aging of the face. Also, it offers the extra benefit of requiring no downtime for recuperation.

Increasing use of less invasive methods

A scope for seeing and surgical instruments with specialized equipment are used in minimally invasive surgery. It reduces volume, shape, and undesirable fat while concentrating on the abnormalities of the face, such as wrinkles and fine lines. Minimally invasive techniques are becoming more popular because they have almost no risk of significant adverse outcomes and need few or no cuts with quick recovery. There is a huge demand for energy-based, minimally invasive procedures for wrinkle reduction, skin tightening, face contouring, and rejuvenation. These mentioned factors are expected to propel the market's expansion.

Market Restraining Factors

The high cost associated with dermal fillers

The growth of the market is anticipated to be constrained throughout the forecast period, despite the wide range of aesthetic applications. One of the main barriers hindering the slowdown in the expansion of the market is the high price tag attached to these products. Dermal filler prices can vary depending on a variety of variables, including the type of procedure performed, the experience and credentials of the practitioner, and the amount of time and effort necessary to complete the surgery or treatment. Thus, the high cost associated with dermal fillers is expected to hinder the market's growth.

Product Outlook

Based on product, the dermal fillers market is segmented into hyaluronic acid, calcium hydroxylapatite, polylactic acid (PLLA), polymethyl-methacrylate microspheres and others. The calcium hydroxylapatite segment acquired a significant revenue share in the dermal fillers market in 2022. The growth is attributed to its safety characteristics. Key players' launches of new goods in this market also contribute to the segment's expansion. Calcium hydroxylapatite (CaHA), which stimulates collagen over time, is an active constituent in the injectable dermal filler. Without treating the area around the tear trough, one can lift sagging soft tissues, lessen lower eyelid lag, and decrease the tear trough.

Type Outlook

On the basis of type, the dermal fillers market is divided into biodegradable and non-biodegradable. The biodegradable segment witnessed the largest revenue share in the dermal fillers market in 2022. This is due to the presence of more product options in this segment than in the non-biodegradable category and because biodegradable products have more varied aesthetic uses. The segment's expansion is also anticipated to be aided by the goods' higher level of safety and solid regulatory approval.

Application Outlook

By application, the dermal fillers market is classified into wrinkle correction, facial contouring, scar treatment, lip enhancement and others. The lip enhancement segment garnered a prominent revenue share in the dermal fillers market in 2022. This is due to the strong volume of lip procedures. The category is anticipated to be driven by the increased demand for cosmetic enhancements of the lips, fueled by the advent of minimally invasive procedures. Lip fillers are a cosmetic treatment that can enhance the volume of lips.

End-Use Outlook

Based on the end-use, the dermal fillers market is bifurcated into MedSpa, cosmetic surgery clinics and hospitals. The hospital segment recorded a promising growth rate in the dermal fillers market in 2022. This is owing to the widespread use of aesthetic procedures like face injectables carried out in hospitals. In addition, the presence of high-tech equipment, staff and other facilities increased their popularity among patients who trust hospitals for various types of filler surgeries, and thus further providing growth opportunities for the segment.

Regional Outlook

Region-wise, the dermal fillers market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the dermal fillers market in 2022. This is due to the region's developing trend of ageless beauty, increased popularity among men, and rising desire for non-surgical aesthetic procedures. In North America, people care a lot about their looks and beauty standards. Due to this, there is a significant demand for dermal fillers to improve face characteristics and lessen aging symptoms.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioplus Co. Ltd, Bioxis pharmaceuticals, Suneva Medical, Inc., Galderma S.A., Allergan PLC (AbbVie, Inc.), Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.), Revance Therapeutics, Inc., Medytox Inc., Merz Pharma GmbH & Co. KGaA and Prollenium Medical Technologies Inc.

Strategies Deployed in Dermal Fillers Market

Mar-2023: Galderma revealed FACE by Galderma, an aesthetic visualization tool that enables aesthetic professionals and patients to visualize injectable treatment results. The FACE by Galderma would enable aesthetic professionals to identify and tailor an individualized treatment plan to meet the needs and aesthetic goals of each patient.

Oct-2022: Prollenium Medical Technologies took over SoftFil, the cosmetic aesthetic leader. This acquisition results in creating synergies between the two brands and further expands and strengthens its presence in international markets.

Sep-2022: Revance Therapeutics received US FDA clearance for its DAXXIFY (DaxibotulinumtoxinA-lanm). The approved product provides temporary improvement of moderate to severe frown lines in adults. 2020-Jan: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.

Feb-2022: Merz Aesthetics released Radiesse® (+) Lidocaine injectable implant for soft tissue augmentation, enhancing mild to severe jawline contour loss in adults over 21. The launch is aimed at meeting the demand of patients seeking a more defined and contoured jawline.

Jan-2022: Galderma completed the acquisition of ALASTIN Skincare®, Inc, which provides a collection of cutting-edge products for optimal procedure results and daily skincare regimens. The acquisition would enhance the dermatology platform of Galderma with a comprehensive collection of scientifically proven products for daily skincare regimens and post-operative care and reinforce the company's commitment to being aesthetic professionals' partner of choice.

Sep-2021: Galderma joined hands with Sofregen Medical, Inc., a medical device company that uses silk protein for tissue building and regeneration. This collaboration would enhance Galderma's capability to build on decades of biostimulation and hyaluronic acid (HA) filler innovation.

Jun-2021: Medytox received approval from the Taiwan Food and Drug Administration for marketing its botulinum toxin Meditoxin in Taiwan. The Approval would allow the company to expand its business in Southeast Asian countries.

Feb-2021: Sinclair Pharma unveiled Lanluma V, for the face and hands and Lanluma X for the rest of the body. The new products are designed to stimulate collagenases to improve the skin's inner structure and shape, reshape and enhance the fullness of different areas of the body, and reduce cellulite.

Oct-2020: Allergan took over Luminera's dermal filler business. The addition of Luminera's entire dermal portfolio and R&D pipeline improves the acquiring company's dermal filler offerings. Further, Luminera's assets perfectly complement Allergan's JUVÉDERM® filler franchise.

Sep-2020: Suneva Medical, Inc. entered into a partnership with Neauvia North America, a subsidiary of Neauvia, a global aesthetics brand. Through this partnership, the company would provide Neauvia North America’s Plasma IQ throughout North America. Plasma IQ complements Suneva Medical's portfolio of facial regenerative aesthetics products that would enable the company to offer proven and validated solutions for aesthetic providers and their patients.

Jun-2020: Galderma launched Restylane Kysse, a newly approved lip filler. The Restylane Kysse is a hyaluronic acid (HA) filler that is proven to last for up to 1 year. The product is approved for lip augmentation and the correction of wrinkles around the upper lips.

Jan-2020: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.

Sep-2019: Merz expanded its geographical footprint by opening a manufacturing site in Dessau. The new production plant would cater to the evolving demand for its Belotero dermal fillers. Moreover, the location of the new facility to secure the international supply of its medical aesthetics products.

Apr-2019: Merz revealed Belotero Revive, a dermal filler product that contains a combination of hyaluronic acid (HA) and glycerol. The Belotero® Revive is designed to enhance hydration, elasticity, and firmness of the skin and to address the appearance of fine lines.

Scope of the Study

Market Segments covered in the Report:

By Type

Biodegradable
Non-biodegradable
By Product

Hyaluronic Acid
Calcium Hydroxylapatite
Polylactic Acid (PLLA)
Polymethyl-methacrylate Microspheres
Others
By End-use

MedSpa
Cosmetic Surgery Clinics
Hospitals
By Application

Wrinkle Correction
Lip Enhancement
Facial Contouring
Scar Treatment
Others
By Geography

North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Companies Profiled

Bioplus Co. Ltd
Bioxis pharmaceuticals
Suneva Medical, Inc.
Galderma S.A.
Allergan PLC (AbbVie, Inc.)
Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.)
Revance Therapeutics, Inc.
Medytox Inc.
Merz Pharma GmbH & Co. KGaA
Prollenium Medical Technologies Inc.
Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free